The prevailing imaging agent is limited because of its large size, which is difficult to get into a solid tumor. Also it seeks out a target located inside the cancers cell and is only able to tag injured cells that are dropping apart instead of actively growing cancer cells. The targeting molecule and radioimaging agent combination designed by Low’s group can be more than 150 times smaller compared to the existing agent and provides much easier penetration through a good tumor to reach all the cells inside, he said. In addition, it has the benefit of targeting an certain region of PSMA exposed externally of cancer cells. Already in clinical trials can be an optical imaging program that involves attaching a fluorescent dye to the targeting molecule and mixing it with a patient’s blood sample.Khanlou served as AHF’s Associate Director of Medicine, Regional Medical Director of Western Region while also keeping the articles of AHF’s Associate Director of Study and the Medical Director and going to physician for the San Fernando Valley and Antelope Valley Health care Centers. Dr. Khanlou in addition has served as Seat of the Pharmacy and Therapeutic Committee at AHF. In addition to his extensive encounter as a practicing HIV/AIDS physician, Dr. Khanlou can be a leading clinical researcher whose research has been published in such prestigious periodicals as the New England Journal of Medication and the Archives of Internal Medicine.